Sickle cell disease

Base Editing (ABE8e) via RNP electroporation (ex vivo) delivery is a rationale-driven therapeutic strategy for Sickle cell disease targeting the HBB c.79G>A (p.Glu27Lys) variant (Pathogenic, missense variant). The editing system (ABE8e-nSpCas9 (adenine base editor)) converts the pathogenic A back to G on the target strand, restoring the wild-type codon. Target tissue: Blood/HSC. Therapeutic goal: Correct the pathogenic HBB Glu7Val (sickle) mutation at chr11:5227002 to restore adult hemoglobin function and prevent hemolysis and vaso-occlusion, or disrupt erythroid BCL11A regulatory elements to . Risk profile: off-target Medium (bystander bases in editing window), delivery complexity Medium, immunogenicity Low.

1. Molecular basis: HBB NM_000518.5(HBB):c.79G>A (p.Glu27Lys) is classified as Pathogenic (ClinVar variation ID 3777010). Molecular consequence: missense variant. Protein change: E27K, V24F. 2. Epidemiology: ~100,000 affected individuals in the US and millions worldwide; highly prevalent in sub-Saharan Africa, India and the Middle East, with carrier frequencies >10% and birth prevalence >1% in some regions. 3. Standard of care: Newborn screening, vaccination, penicillin prophylaxis, hydroxyurea, chronic transfusions with iron chelation, and allogeneic hematopoietic stem cell transplantation for a minority with suitable donors; newer disease-modifying drugs (voxelotor, crizanlizumab, L-glutamine) provide partial benefit but 4. Pipeline: Multiple gene-addition and gene-editing programs targeting HBB or BCL11A: lentiviral gene therapy (betibeglogene autotemcel; Phase II/III and approval in some regions), ex vivo CRISPR/Cas9 editing of the BCL11A erythroid enhancer (exagamglogene autotemcel, exa-cel/Casgevy; Phase II/III leading to fi 5. ABE clinical validation: ABE8e (Richter et al. 2020, Nat Biotechnol) achieves ~1.7x higher editing efficiency than ABE7.10. VERVE-101 demonstrated first-in-human LNP-ABE liver editing with 55-66% PCSK9 reduction (Raal et al. 2025, NEJM). Beam Therapeutics is advancing multiple ABE programs.

1. No published data specifically correcting HBB c.79G>A (p.Glu27Lys) with Base Editing (ABE8e); strategy is based on general principles and must be validated preclinically. 2. PAM availability and bystander base analysis for the specific genomic context have not been performed. If no canonical NGG PAM positions the target within the editing window, PAM-flexible variants (SpRY) may be needed. 3. Long-term durability, off-target genome-wide effects, and immunogenicity in the target patient population require thorough preclinical and clinical evaluation.

For the canonical sickle variant HBB c.20A>T (p.Glu7Val), ex vivo CRISPR editing that raises fetal hemoglobin is the most clinically validated gene-editing strategy currently available. The therapeutic effect does not repair the HBB codon directly, but it is directly relevant to this genotype because it reduces HbS polymerization pressure by re-inducing HbF in autologous erythroid cells.

ClinVar lists HBB c.20A>T as Pathogenic and this variant is the molecular basis of classic sickle cell disease. In the phase 3 CLIMB SCD-121 study of exagamglogene autotemcel, severe sickle cell disease patients treated with CRISPR-Cas9 edited autologous hematopoietic stem cells had marked reduction of vaso-occlusive crises and durable clinical benefit (PMID:38661449). A 2025 review of gene therapies for hemoglobinopathies also places BCL11A enhancer editing among the leading clinically validated approaches for sickle cell disease (PMID:41223813). Because the mechanism is HbF reactivation rather than allele-specific repair, the strategy is robust to the exact HbS codon context and avoids needing efficient in vivo delivery to all erythroid precursors.

This is not a direct correction of p.Glu7Val, so edited patients still carry the pathogenic HBB allele. The approach requires myeloablative conditioning, autologous stem-cell collection, and specialized transplant infrastructure, which materially limits scalability and raises toxicity concerns. The evidence base is strongest for severe disease populations treated at expert centers, and long-term durability beyond the currently reported follow-up windows still needs continued surveillance. It also does not answer whether direct in vivo correction of HBB c.20A>T will ever outperform HbF reactivation on risk-benefit grounds.